Revolution Medicines Completes Acquisition of EQRx
November 09, 2023 09:10 ET
|
Revolution Medicines, Inc.
Acquisition Expected to Add Approximately $1.1 Billion in Net Cash to Revolution Medicines’ Balance Sheet, Supporting Late-Stage Development of RAS(ON) Inhibitor Investigational Drugs Sandra Horning,...
HistoSonics Edison System Recognized With BioTech Breakthrough Award For “MedTech Innovation Of The Year”
November 08, 2023 08:02 ET
|
BioTech Breakthrough
LOS ANGELES, Nov. 08, 2023 (GLOBE NEWSWIRE) -- BioTech Breakthrough, a leading independent market intelligence organization that evaluates and recognizes standout life sciences and biotechnology...
Revolution Medicines Reports Third Quarter 2023 Financial Results and Update on Corporate Progress
November 06, 2023 16:05 ET
|
Revolution Medicines, Inc.
Promising clinical data for RMC-6236, a RASMULTI(ON) Inhibitor, and RMC-6291, a RASG12C(ON) Inhibitor, presented at AACR-NCI-EORTC (“Triple”) and ESMO Meetings Acquisition of EQRx, Inc. expected to...
Revolution Medicines Presents Promising Clinical Activity and Safety Data from Phase 1/1b Trial of RMC-6236
October 22, 2023 02:30 ET
|
Revolution Medicines, Inc.
REDWOOD CITY, Calif., Oct. 22, 2023 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing targeted therapies for RAS-addicted cancers, today...
[Latest] Global Precision Fermentation Market Size/Share Worth USD 25.54 Billion by 2032 at a 45% CAGR: Custom Market Insights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth, Growth Rate, Value)
October 09, 2023 18:30 ET
|
Custom Market Insights
Austin, TX, USA, Oct. 10, 2023 (GLOBE NEWSWIRE) -- Custom Market Insights has published a new research report titled “Precision Fermentation Market Size, Trends and Insights By Ingredient (Whey...
Revolution Medicines Doses First Patient in Phase 1/1b Clinical Trial of RMC-9805, an Oral, Covalent, Mutant-Selective KRASG12D(ON) Inhibitor
September 19, 2023 07:00 ET
|
Revolution Medicines, Inc.
KRASG12D(ON) Inhibitor with highly differentiated mechanism of action being evaluated in patients with cancers harboring the KRASG12D mutation, the most common driver of RAS-addicted human cancers ...
Revolution Medicines Announces Publication Describing Molecular Basis of Tri-Complex Inhibitors Targeting Oncogenic RAS(ON) Proteins
August 17, 2023 16:05 ET
|
Revolution Medicines, Inc.
Science Report on KRASG12C(ON)-Selective Inhibitors Provides Preclinical Proof-of-Principle for Company's RAS Innovation Engine and Broad Pipeline REDWOOD CITY, Calif., Aug. 17, 2023 (GLOBE...
Revolution Medicines to Report Financial Results for Second Quarter 2023 After Market Close on August 8, 2023
August 03, 2023 16:05 ET
|
Revolution Medicines, Inc.
REDWOOD CITY, Calif., Aug. 03, 2023 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing novel targeted therapies for RAS-addicted cancers,...
[Latest] Global Precision Medicine Market Size/Share Worth USD 189.64 Billion by 2030 at a 11.5% CAGR: Custom Market Insights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth, Growth Rate, Value)
July 20, 2023 11:30 ET
|
Custom Market Insights
Austin, TX, USA, July 20, 2023 (GLOBE NEWSWIRE) -- Custom Market Insights has published a new research report titled “Precision Medicine Market Size, Trends and Insights By Technology (Big data...
Precision Fermentation Market Size Will Grow USD 6,385 Million by 2032
July 18, 2023 08:07 ET
|
Precedence Research
Ottawa, July 18, 2023 (GLOBE NEWSWIRE) -- The precision fermentation market size was valued at USD 1,930 million in 2022. Precision fermentation is a technology that uses microorganisms, such as...